静脉铁剂相关低磷血症  

Intravenous iron administration induced hypophosphatemia

作　　者：吕芳 纪立农[1] LYU Fang;JI Li-nong(Department of Endocrinology and Metabolism,Peking University People s Hospital,Beijing 100044,China)

机构地区：[1]北京大学人民医院内分泌科,北京100044

出　　处：《中华骨质疏松和骨矿盐疾病杂志》2020年第3期261-265,共5页Chinese Journal Of Osteoporosis And Bone Mineral Research

摘　　要：静脉铁剂常用于口服铁剂治疗效果不佳或无法耐受口服铁剂的缺铁性贫血患者。某些静脉铁剂(如羧基麦芽糖铁、异麦芽糖酐铁、蔗糖铁、多聚麦芽糖铁等)通过升高成纤维细胞生长因子23导致低磷血症,大多数患者表现为轻度低磷,症状缺乏特异性。反复长期使用静脉铁剂可能导致骨软化和骨折等严重结果。本文对该病进行综述,旨在提醒临床医生重视静脉铁剂相关低磷血症。Intravenous iron is commonly used in iron deficiency anemia when patients are unresponsive to or intolerant of oral iron.Certain forms of intravenous iron(such as ferric carboxymaltose,iron isomaltoside,iron dextran,iron polymaltose)induced hypophosphatemia by increasing circulating concentrations of fibroblast growth factor 23(FGF-23).Most patients have mild hypophosphatemia without specific clinical manifestations.Repeated intravenous iron administra-tion can induce osteomalacia and bone fragility.Therefore,we reviewed intravenous iron administration induced hypophosphatemia,to remind doctors to learn it.

关 键 词：静脉铁剂 低磷血症 成纤维细胞生长因子23 骨软化 

分 类 号：R681[医药卫生—骨科学]